Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · New York | Tumor & fibroid embolization · Pennsylvania | |
|---|---|---|
| Surgeons, 2024 | 22 | 19 |
| Medicare fee-for-service cases | 1,661 | 908 |
| Growth since 2019 (Medicare FFS) | +10%/yr | −0.7%/yr |
| Forecast cases (Medicare FFS) | 3,360 in 2030 | 1,830 in 2030 |
| Forecast growth | +12%/yr to 2030 | +12%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.9 | 0.7 |
| Medicare Advantage share | 57% | 58% |
| Out of hospital | 48% (+40 pts since 2019) | 27% (+27 pts since 2019) |
| Cases per surgeon | 76 | 48 |
| Top 10 surgeons' share | 79% | 75% |
| Surgeons growing | 4 | 3 |
| New since the base year | 6 | 5 |
| Likely to stop billing it | 2 by 2026 | 6 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $62K | $19K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.